ClinicalTrials.gg
Not yet recruitingNCT07939945Updated Nov 16, 2026

Effect of Posterior TAP Block on ANI-Guided Remifentanil Consumption in Gynecologic Laparotomy

An interventional study of Ultrasound-Guided Bilateral Posterior TAP Block and Bupivacaine in Intraoperative and Postoperative Opioid Requirements, Postoperative Pain and Laparotomy, sponsored by Samsun University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Samsun University · Not applicable, Interventional, and Other

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 364 studies testing bupivacaine in Pain, Postoperative — 57 open to participants now, 60 under way, 5 of them phase 3. Bupivacaine · Pain, Postoperative.

Planned enrollment
191st of 364
64 · median 70
Started
2026
with 21 others
No phase
111 of 364
26 open now
Primary completion
2027-03
later than 42 of 59 live
Registered
363rd of 364
by date

Among the 364 studies testing bupivacaine in Pain, Postoperative, this one is the 191st largest by planned enrollment, is one of 22 that started in 2026, is one of 111 with no phase, reaches primary completion later than 42 of the 59 other live ones, and was the 363rd registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,231 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

57 of the 364 studies testing bupivacaine in Pain, Postoperative are open now, in 8 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About bupivacaine

Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 679 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 364 studies testing bupivacaine in Pain, Postoperative, or all of them as a file.
02

Study summary

The aim of this study is to evaluate the effect of preoperative posterior transversus abdominis plane (TAP) block on intraoperative remifentanil consumption in patients undergoing gynecological laparotomy under Analgesia Nociception Index (ANI)-guided general anesthesia.

Read the detailed description

A standardized anesthesia and analgesia protocol will be applied to all participants undergoing elective gynecological laparotomy. Participants will be randomly divided into two groups: those receiving preoperative ultrasound-guided bilateral posterior transversus abdominis plane (TAP) block and those without block. Intraoperative monitoring will include heart rate, noninvasive mean arterial pressure, oxygen saturation, Analgesia Nociception Index (ANI), and Bispectral Index (BIS). Remifentanil infusion will be adjusted according to ANI values, with a target range of 50-70. Intraoperative remifentanil consumption and postoperative analgesia will be compared between the two groups.

03

Conditions studied

  • Intraoperative and Postoperative Opioid Requirements
  • Postoperative Pain
  • Laparotomy

Browse trials for

Keywords

  • Posterior TAP Block
  • Analgesia Nociception Index
  • Gynecologic Surgery
  • Multimodal Analgesia
  • Regional Anesthesia
  • Postoperative Analgesia
  • Transversus Abdominis Plane Block
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients aged 18 to 70 years
  • Scheduled for elective gynecologic laparotomy under general anesthesia
  • I to III
  • Planned perioperative management according to the study protocol
  • Written obtained

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate
  • to posterior transversus abdominis plane block
  • Allergy or to local anesthetic agents or study medications
  • Coagulopathy or ongoing anticoagulant therapy that precludes regional anesthesia
  • Infection at the planned block site
  • greater than 35 kg/m2
  • Chronic opioid use
  • Pregnancy
  • Inability to understand the pain scoring system or use patient-controlled analgesia
  • Conversion to a surgical procedure outside the planned gynecologic laparotomy protocol
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Outcomes assessor)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Posterior TAP Block Group

    Participants in this group will receive preoperative ultrasound-guided bilateral posterior transversus abdominis plane (TAP) block in addition to standardized general anesthesia. Intraoperative remifentanil infusion will be adjusted according to ANI values, targeting a range of 50-70.

    Procedure: Ultrasound-Guided Bilateral Posterior TAP Block · Drug: Bupivacaine

  • No intervention
    Control Group

    Participants in this group will not receive a TAP block. Standardized general anesthesia will be administered, and intraoperative remifentanil infusion will be adjusted according to ANI values, targeting a range of 50-70.

Interventions

  • ProcedureUltrasound-Guided Bilateral Posterior TAP Block

    Ultrasound-guided bilateral posterior transversus abdominis plane (TAP) block will be performed preoperatively in patients undergoing gynecological laparotomy.

  • Bupivacaine 0.25% (2.5 mg/mL) will be administered as a single-shot, ultrasound-guided bilateral posterior transversus abdominis plane (TAP) block before surgery. A total volume of 40 mL (100 mg) will be administered, with 20 mL (50 mg) injected on each side. The intervention will be performed only in the experimental group.

06

What researchers measure

Primary outcomes

  1. Intraoperative Remifentanil Consumption

    Intraoperative remifentanil consumption will be calculated by dividing the total remifentanil dose by patient body weight and infusion duration, expressed in µg/kg/min.

    Time frame: Intraoperative period

Secondary outcomes

  1. Numeric rating scale for postoperative pain intensity

    Evaluated with a Numerical rating scale (NRS) from 0 to 10. (0=no pain; 10=worst imaginable pain)

    Time frame: up to 24 hours (Will be evaluated at 1, 3, 6, 9, 12, 18, 24 hours)

  2. Quality of Recovery - 15 score

    The impact of surgical and anesthetic interventions on perioperative quality of life and ability to resume routine life activities will be assessed using the Quality of Recovery (QoR) tool. Each question is scored between 0 and 10. The survey result varies between 0-150 points based on the answers given by the patients. Higher scores indicate better recovery.

    Time frame: Postoperative 24th hour

  3. Fentanyl consumption at 30 minutes after arrival in the PACU(post anesthesia care unit)

    Postoperative pain will be assessed using the Numeric Rating Scale (NRS) from 0 to 10. Fentanyl will be administered when the NRS score is ≥4, and the total fentanyl consumption will be recorded in micrograms (µg).

    Time frame: 30 minutes

07

Study locations

1 site
  • Samsun University - Samsun Education and Research Hospital
    Samsun, Turkey (Türkiye)
    • Sevda Akdeniz · Contactakdenizsevda@yahoo.com · +90 505 399 86 51
    • Emre C Soydan · Contact+905366422896
08

References and documents

Publications

  • Griffiths JD, Middle JV, Barron FA, Grant SJ, Popham PA, Royse CF. Transversus abdominis plane block does not provide additional benefit to multimodal analgesia in gynecological cancer surgery. Anesth Analg. 2010 Sep;111(3):797-801. doi: 10.1213/ANE.0b013e3181e53517. Epub 2010 Jun 14. PubMed 20547822 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Mar 2027, 3 months later.

Of 2,096 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 3 months is below that.

Counting every sponsor, half of 2,109 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2026
First posted
Nov 16, 2026
StartEst.
Nov 20, 2026
Primary completionEst.
Mar 1, 2027
CompletionEst.
Mar 30, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07939945
Lead sponsor
Samsun University
Responsible party
Sevda Akdeniz,MD (Associate Professor, Samsun University) — Principal investigator
First posted
Nov 16, 2026
Start date
Nov 20, 2026 (estimated)
Primary completion
Mar 1, 2027 (estimated)
Completion
Mar 30, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Sevda Akdeniz
Contact
akdenizsevda@yahoo.com
+90 505 399 86 51
Emre C Soydan
Contact
emrecansoydanmd@gmail.com
+905366422896
Sevda Akdeniz
principal investigator · Samsun University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupivacaine

Start the discussion